Pharmacokinetics and metabolism of KW-4490, a selective phosphodiesterase 4 inhibitor: Difference in excretion of KW-4490 and acylglucuronide metabolites between rats and cynomolgus monkeys

References

• Albert C, Barbier O, Valée M, Beaudry G, Bélanger A, Hum DW. Distribution of uridine diphosphate-glucuronosyltransferase (UGT) expression and activity in cynomolgus monkey tissues: Evidence for differential expression of steroid-conjugating UGT enzymes in steroid target tissues. Endocrinology 2000; 141: 2472–2480
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Novel approaches and targets for treatment of chronic obstructive pulmonary disease. American Journal of Respiration and Critical Care Medicine 1999; 160: S72–S79
   PubMed Web of Science ®Google Scholar
• Boichot E, Wallace JL, Germain N, Corbel M, Lugnier C, Lagente V, Bourguignon JJ. Anti-inflammatory activities of a new series of selective phosphodiesterase 4 inhibitors derived from 9-benzyladenine. Journal of Pharmacology and Experimental Therapeutics 2000; 292: 647–653
   PubMedGoogle Scholar
• Bouska JJ, Bell RL, Goodfellow CL, Stewart AO, Brooks CDW, Carter GW. Improving the in vivo duration of 5-lipoxygenase inhibitor application of an in vitro glucuronosyltransferase assay. Drug Metabolism and Disposition 1997; 25: 1032–1038
   PubMed Web of Science ®Google Scholar
• Branette MS, Christensen SB, Essayan DM, Grous M, Prabhakar U, Rush JA, Kagey-Sobotka A, Torphy TJ. SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions. Journal of Pharmacology and Experimental Therapeutics 1998; 284: 420–426
   PubMedGoogle Scholar
• Chandra P, Brouwer KLR. The complexities of hepatic drug transport: Current knowledge and emerging concepts. Pharmacology Research 2004; 21: 719–735
   PubMed Web of Science ®Google Scholar
• Christensen SB, Guider A, Foster CJ, Gleason JG, Bender PE, Karpinski JM, DeWolf WE, Barnette MS, Underwood DC, Griswold DE, et al. 1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosphodiesterase 4 for the treatment of asthma. Journal of Medicine and Chemistry 1998; 41: 821–835
   PubMed Web of Science ®Google Scholar
• De Rosalmeida MC, Saraiva LDS, Da Graca JRV, Ivo BB, Da Nóbrega MV, Gondim FA, Rola FH, Dos Santos AA. Sildenafil, a phosphodiesterase-5 inhibitor, delays gastric emptying and gastrointestinal transit of liquid in awake rats. Digestion Disease Science 2003; 48: 2064–2068
   PubMedGoogle Scholar
• Han YH, Kato Y, Haramura M, Ohta M, Matsuoka H, Sugiyama Y. Physicochemical parameters responsible for the affinity of methotrexate analogs for rat canalicular multispecific organic anion transporter (cMOAT/MRP2). Pharmacology Research 2001; 18: 579–586
   PubMed Web of Science ®Google Scholar
• Hirom PC, Millburn P, Smith RL, Williams RT. Species variation in the threshold molecular-weight factor for the biliary excretion of organic anions. Biochemistry Journal 1972; 129: 1071–1077
   PubMed Web of Science ®Google Scholar
• Jiunn HL, Layne EL, Edgar HU, Daniel ED. Kinetic studies on the competition between famotidine and cimetidine in rats. Evidence of multiple renal secretory systems for organic cations. Drug Metabolism and Disposition 1988; 16: 52–56
   PubMedGoogle Scholar
• Losco PE, Evans EW, Barat SA, Blackshear PE, Reyderman L, Fine JS, Bober LA, Anthes JC, Mirro EJ, Cuss FM. The toxicity of SCH 351591, a novel phosphodiesterase-4 inhibitor, in cynomolgus monkeys. Toxicology and Pathology 2004; 32: 295–308
   PubMed Web of Science ®Google Scholar
• Naritomi Y, Terashita S, Kimura S, Suzuki A, Kagayama A, Sugiyama Y. Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metabolism and Disposition 2001; 29: 1316–1324
   PubMed Web of Science ®Google Scholar
• Ninuma K, Kato Y, Suzuki H, Tyson CA, Weizer V, Dabss JE, Froehlich R, Green CE, Sugiyama Y. Primary active transport of organic anions on bile canalicular membrane in humans. American Journal of Physiology and Gastrointestinal Liver Physiology 1999; 276: G1153–G1164
   Web of Science ®Google Scholar
• Obach RS. Metabolism of ezlopitant, a nonpeptidic substance p receptor antagonist, in liver microsomes: enzyme kinetics, cytochrome P450 isoform identity, and in vitro–in vivo correlation. Drug Metabolism and Disposition 2000; 28: 1069–1076
   PubMed Web of Science ®Google Scholar
• Sarnelli G, Sifrim D, Tack J. Influence of sildenafil on gastric sensorimotor function in humans. American Journal of Physiology and Gastrointestinal Liver Physiology 2004; 287: G988–G992
   Google Scholar
• Soars MG, Riley RJ, Burchell B. Evaluation of the marmoset as a model species for drug glucuronidation. Xenobiotica 2001; 31: 849–860
   PubMed Web of Science ®Google Scholar
• Spahn-Langguth H, Benet LZ. Acyl glucuronides revisited: Is the glucuronidation process a toxification as well as a detoxification %. Drug Metabolism Reviews 1992; 24: 5–48
   PubMed Web of Science ®Google Scholar
• Tahara H, Kusuhara H, Chida H, Fuse E, Sugiyama Y. Is the monkey an appropriate animal model to examine drug–drug interactions involving renal % Effect of probenecid on the renal elimination of H2 receptor antagonists. Journal of Pharmacology and Experimental Therapeutics 2006; 316: 1187–1194
   PubMed Web of Science ®Google Scholar
• Tahara H, Shono M, Kusuhara H, Kinoshita H, Fuse E, Takadate A, Otagiri M, Sugiyama Y. Molecular cloning and functional analyses of OAT1 and OAT3 from cynomolgus monkey kidney. Pharmacology Research 2005; 22: 647–660
   PubMed Web of Science ®Google Scholar
• Teixeira MM, Gristwood RW, Cooper N, Hellewell PG. Phosphodiesterase (PDE) 4 inhibitors: anti-inflammatory drugs of the %. Trends in Pharmacology Science 1997; 18: 164–170
   PubMed Web of Science ®Google Scholar
• Torphy TJ. Phosphodiesterase isozymes. American Journal of Respiration and Critical Care Medicine 1998; 157: 351–370
   PubMed Web of Science ®Google Scholar
• Yoshimura T, Tanaka S, Sakurai H, Nagai Y, Yamada K, Katayama S, Abe S, Yamatsu I. Metabolism and excretion of a new 5-lipoxygenase inhibitor in rats, guinea-pigs, beagles and rhesus monkeys. Xenobiotica 1991; 21: 627–634
   PubMed Web of Science ®Google Scholar